Abcam, ab250725, Anti-DDAH2 antibody [EPR15508(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal DDAH2 antibody. Carrier free. Suitable for WB and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR15508(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Rat, Mouse,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250725 is the carrier-free version of
ab184166
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DDAH2 or Dimethylarginine Dimethylaminohydrolase 2 is an enzyme encoded by the human DDAH2 gene. With a molecular mass of approximately 30 kDa DDAH2 plays key role in the regulation of nitric oxide (NO) levels by breaking down asymmetric dimethylarginine (ADMA) an endogenous inhibitor of nitric oxide synthase (NOS). DDAH2 expression is found in a variety of tissues including the heart liver and kidney indicating its widespread functional importance in these organs.
Biological function summary
DDAH2 regulates nitric oxide production affecting processes such as vasodilation and vascular homeostasis. This enzyme also interacts in complex regulatory networks that modulate blood flow and blood pressure. By controlling ADMA concentration DDAH2 indirectly influences endothelial function and cardiovascular health. The enzyme’s role in maintaining NO levels makes it integral to processes that rely on proper endothelial signaling.
Pathways
Nitric oxide signaling and the methylarginine metabolic pathways are two significant areas involving DDAH2. In the NO signaling pathway DDAH2 impacts the synthesis of NO by modulating inhibitor levels of NOS. In the methylarginine pathway DDAH2 is closely related to the enzyme PRMT (Protein Arginine Methyltransferase) as it regulates the availability of methylarginine substrates. DDAH2’s activity harmonizes the balances within these pathways ensuring effective signaling and metabolic regulation.
Altered DDAH2 activity has connections to cardiovascular diseases and hypertension. Dysfunctional DDAH2 can lead to elevated ADMA levels which correlate with increased cardiovascular risk and impaired endothelial function. Within these diseases DDAH2’s interaction with NOS is important; improper NO production resulting from dysregulated enzyme activity affects cardiovascular health. Addressing DDAH2 malfunction holds therapeutic potential for managing related vascular disorders.